Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study
ABSTRACT Introduction The clinical application of lazertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has extended to the treatment of EGFR‐mutant non‐small‐cell lung cancer (NSCLC); however, the effects of its dose modification on its efficacy and safet...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.70083 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850109198850850816 |
|---|---|
| author | Mi‐Hyun Kim Min Ki Lee Ji Eun Park Sun Hyo Park Tae Won Jang Chi Young Jung Insu Kim Seong Hoon Yoon June Hong Ahn Hyun‐Kyung Lee Jin Han Park Sun Ha Choi Jung Seop Eom |
| author_facet | Mi‐Hyun Kim Min Ki Lee Ji Eun Park Sun Hyo Park Tae Won Jang Chi Young Jung Insu Kim Seong Hoon Yoon June Hong Ahn Hyun‐Kyung Lee Jin Han Park Sun Ha Choi Jung Seop Eom |
| author_sort | Mi‐Hyun Kim |
| collection | DOAJ |
| description | ABSTRACT Introduction The clinical application of lazertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has extended to the treatment of EGFR‐mutant non‐small‐cell lung cancer (NSCLC); however, the effects of its dose modification on its efficacy and safety have not yet been adequately established. Methods This prospective, multicenter, observational cohort study aims to evaluate the clinical implications of adjusting the lazertinib dose. Patients will be categorized into two groups based on the lazertinib dose administered during the initial 12 weeks of treatment in routine clinical practice: 160 and 240 mg groups. The primary endpoints are progression‐free survival in the 160 mg group and identifying risk factors associated with dose modification during the 12‐week period. Discussion The findings from the present study will provide real‐world insights into the clinical factors leading to lazertinib dose adjustments and deepen our understanding of the efficacy and safety of lazertinib in patients with NSCLC. Our research will contribute toward optimizing medical strategies for NSCLC treatment and aid clinicians in making accurate clinical decisions regarding dose modifications in routine practice. |
| format | Article |
| id | doaj-art-006fc5625fe848f6b977158216189eaa |
| institution | OA Journals |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-006fc5625fe848f6b977158216189eaa2025-08-20T02:38:07ZengWileyThoracic Cancer1759-77061759-77142025-05-011610n/an/a10.1111/1759-7714.70083Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort StudyMi‐Hyun Kim0Min Ki Lee1Ji Eun Park2Sun Hyo Park3Tae Won Jang4Chi Young Jung5Insu Kim6Seong Hoon Yoon7June Hong Ahn8Hyun‐Kyung Lee9Jin Han Park10Sun Ha Choi11Jung Seop Eom12Department of Internal Medicine Pusan National University School of Medicine Busan Republic of KoreaDepartment of Internal Medicine Pusan National University School of Medicine Busan Republic of KoreaDepartment of Internal Medicine, School of Medicine Kyungpook National University Daegu Republic of KoreaDivision of Pulmonology, Respiratory Center, Keimyung University Dongsan Hospital Keimyung University School of Medicine Daegu Republic of KoreaDepartment of Internal Medicine Kosin University Medical College Busan Republic of KoreaDepartment of Internal Medicine Catholic University of Daegu School of Medicine Daegu Republic of KoreaDepartment of Internal Medicine, College of Medicine Dong‐A University Busan Republic of KoreaDepartment of Internal Medicine Pusan National University Yangsan Hospital Yangsan Republic of KoreaDepartment of Internal Medicine, College of Medicine Yeungnam University Daegu Republic of KoreaDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Inje University Busan Paik Hospital Inje University College of Medicine Busan Republic of KoreaDivision of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Haeundae Paik Hospital Inje University College of Medicine Busan Republic of KoreaDepartment of Internal Medicine, School of Medicine Kyungpook National University Chilgok Hospital Daegu Republic of KoreaDepartment of Internal Medicine Pusan National University School of Medicine Busan Republic of KoreaABSTRACT Introduction The clinical application of lazertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has extended to the treatment of EGFR‐mutant non‐small‐cell lung cancer (NSCLC); however, the effects of its dose modification on its efficacy and safety have not yet been adequately established. Methods This prospective, multicenter, observational cohort study aims to evaluate the clinical implications of adjusting the lazertinib dose. Patients will be categorized into two groups based on the lazertinib dose administered during the initial 12 weeks of treatment in routine clinical practice: 160 and 240 mg groups. The primary endpoints are progression‐free survival in the 160 mg group and identifying risk factors associated with dose modification during the 12‐week period. Discussion The findings from the present study will provide real‐world insights into the clinical factors leading to lazertinib dose adjustments and deepen our understanding of the efficacy and safety of lazertinib in patients with NSCLC. Our research will contribute toward optimizing medical strategies for NSCLC treatment and aid clinicians in making accurate clinical decisions regarding dose modifications in routine practice.https://doi.org/10.1111/1759-7714.70083dose modificationepidermal growth factor receptorlazertinibtreatment outcome |
| spellingShingle | Mi‐Hyun Kim Min Ki Lee Ji Eun Park Sun Hyo Park Tae Won Jang Chi Young Jung Insu Kim Seong Hoon Yoon June Hong Ahn Hyun‐Kyung Lee Jin Han Park Sun Ha Choi Jung Seop Eom Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study Thoracic Cancer dose modification epidermal growth factor receptor lazertinib treatment outcome |
| title | Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study |
| title_full | Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study |
| title_fullStr | Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study |
| title_full_unstemmed | Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study |
| title_short | Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study |
| title_sort | impact of modifying lazertinib doses on effectiveness and safety in patients with egfr positive advanced lung cancer a multicenter prospective observational cohort study |
| topic | dose modification epidermal growth factor receptor lazertinib treatment outcome |
| url | https://doi.org/10.1111/1759-7714.70083 |
| work_keys_str_mv | AT mihyunkim impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT minkilee impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT jieunpark impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT sunhyopark impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT taewonjang impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT chiyoungjung impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT insukim impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT seonghoonyoon impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT junehongahn impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT hyunkyunglee impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT jinhanpark impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT sunhachoi impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy AT jungseopeom impactofmodifyinglazertinibdosesoneffectivenessandsafetyinpatientswithegfrpositiveadvancedlungcanceramulticenterprospectiveobservationalcohortstudy |